Research Solutions (Nasdaq ticker: RSSS) is a company that provides SaaS and AI-driven scientific research tools. On November 11, the company announced that it had completed its largest transaction to date: signing an enterprise-level Scite agreement worth $1 million with a Fortune 500 biopharmaceutical company.
This agreement will expand the long-term cooperative relationship between customers and Article Galaxy. Scite will be fully deployed across all of its research teams, enabling researchers and internal tools to utilize Scite's Smart Citations and scientific literature search functions.
AI Deployment Method for Large Pharmaceutical Enterprises
Large R&D organizations are building new systems for evidence-based literature retrieval, mechanism of action research, patent landscape analysis, and pharmacovigilance. The reliability of such systems depends on their ability to read and cite from reliable sources. Generalized models have limited coverage of academic content and may produce "illusory" citations; they are also unable to distinguish between conclusions supported by evidence and those that are controversial. Scite addresses these issues at the infrastructure level.
Research Solutions President and CEO Roy W. Olivier stated: "Every large R&D organization we have contacted is rebuilding their search and discovery tools, and they all face the same problem: AI agents need to have credible access to scientific literature. This agreement is the largest of its kind in our history, and it is not an isolated case. It reflects the demand we see across the entire process, from companies that need to build their systems on real evidence."
The agreement was reached after months of corporate evaluation, which included on-site demonstrations, technical trials, as well as reviews by procurement, legal, information security, technical architecture, and customer AI governance departments, before ultimately gaining approval from senior management. The agreement covers the enterprise-level deployment of the Scite platform, as well as full Scite API access rights and additional Scite datasets. These products enable the organization's internal tools to search for and evaluate peer-reviewed literature within existing workflows, cite evidence behind answers, verify the authenticity of claims, and obtain licensed full texts through existing authorization.
About Research Solutions
Research Solutions, Inc. (Nasdaq ticker: RSSS) is a holding company that provides software and AI solutions for corporate R&D teams and academic institutions. Through Scite and Article Galaxy products, the company combines proprietary data, integrated workflows, and access to infrastructure to help modern researchers and their AI systems find, trust, and apply scientific research more quickly.
For more information, please visit: www.researchsolutions.com | LinkedIn | Facebook | X
About Scite
Scite is a research platform driven by AI, which helps researchers discover and evaluate scientific literature. Its Smart Citations technology analyzes the full text of cited articles to show whether subsequent studies support, mention, or refute the relevant findings. Scite is currently used by millions of researchers and can be accessed through a web platform, browser extensions, and Zotero plugins. For more information, please visit https://www.scite.ai. Scite is a product of Research Solutions (Nasdaq ticker: RSSS).
About Article Galaxy
Article Galaxy is a scientific literature acquisition platform that provides research and development teams and academic institutions with on-demand access to over 80 million full-text, peer-reviewed journal articles. Article Galaxy processes each request through the most cost-effective and compliant pathways, whether through existing subscriptions, open access, or one-time purchases, and includes article-level reuse rights in every transaction. Researchers can directly order full texts from PubMed, Google Scholar, and more than 70 other discovery environments. For more information, please visit https://www.articlegalaxy.com. Article Galaxy is a product of Research Solutions (Nasdaq ticker: RSSS).
Important Notice Regarding Forward-Looking Statements
Certain statements in this press release may contain “forward-looking statements” regarding future events and future performance. Except for statements of historical facts, all other statements may be considered forward-looking statements. These statements are based on the company’s management’s current expectations, estimates, projections, and judgments regarding its market, as well as related beliefs and assumptions. Words such as “expected,” “estimated,” “target,” “intended,” “projected,” “planned,” “believes,” “seeks,” “estimates,” “efforts,” “strives,” “possible,” and their variations, as well as similar expressions, are intended to identify such forward-looking statements. Readers should be aware that these forward-looking statements are subject to a number of risks, uncertainties, and assumptions that are difficult to predict, estimate, or verify. As a result, actual results may differ significantly and unfavorably from those expressed in any forward-looking statements. Such risks and uncertainties include factors described in the company’s most recent 10-K annual report, as well as any revisions or additions that may be made in subsequent 10-Q quarterly reports or other reports submitted to the U.S. Securities and Exchange Commission (SEC). Examples of forward-looking statements in this press release include statements regarding customer demand, the company’s pipeline, and the expected adoption of its AI product. Readers are cautioned not to rely too heavily on these forward-looking statements. Forward-looking statements are only valid as of the date of this release, and the company has no obligation to publicly update any revised results. For more information, please refer to the documents submitted by the company to the SEC.
